Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysis
Phase 4
- Conditions
- Secondary hyperpapathyroidism
- Registration Number
- JPRN-UMIN000033514
- Lead Sponsor
- Fujita Memorial Hospital, Department of Internal Medicine
- Brief Summary
Parathyroid hormone significantly decreased in the change group from cinacalcet to etelcalcetide after 12 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with malignant tumors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method oninferiority of etelcalcetide to cinacalcet on serum parathyroid hormone suppression after 12 months
- Secondary Outcome Measures
Name Time Method Evaluation of safety of etelcalcetide, especially including hypocalcemia